Based on the key indicators related to Kymera Therapeutics' liquidity, profitability, solvency, and operating efficiency, Kymera Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Kymera Therapeutics' Non Currrent Assets Other are relatively stable compared to the past year. As of 03/23/2025, Other Assets is likely to grow to about 11 M, while Other Current Liabilities is likely to drop slightly above 19.6 M. Key indicators impacting Kymera Therapeutics' financial strength include:
The financial analysis of Kymera Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Kymera Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Kymera Therapeutics competes with Foghorn Therapeutics, Shattuck Labs, Monte Rosa, Nurix Therapeutics, and Revolution Medicines. Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 160 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Kymera Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Kymera Therapeutics's current stock value. Our valuation model uses many indicators to compare Kymera Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kymera Therapeutics competition to find correlations between indicators driving Kymera Therapeutics's intrinsic value. More Info.
Kymera Therapeutics is rated below average in return on equity category among its peers. It is rated fifth overall in return on asset category among its peers . At this time, Kymera Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Kymera Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Kymera Therapeutics Systematic Risk
Kymera Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kymera Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Kymera Therapeutics correlated with the market. If Beta is less than 0 Kymera Therapeutics generally moves in the opposite direction as compared to the market. If Kymera Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kymera Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kymera Therapeutics is generally in the same direction as the market. If Beta > 1 Kymera Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Kymera Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kymera Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Kymera Therapeutics growth as a starting point in their analysis.
Kymera Therapeutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kymera Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kymera Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kymera Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Kymera Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kymera Therapeutics's daily price indicators and compare them against related drivers.
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.